CCR5 pharmacology methodologies and associated applications.

作者: Roy Mansfield , Sarah Able , Paul Griffin , Becky Irvine , Ian James

DOI: 10.1016/S0076-6879(09)05202-1

关键词:

摘要: Abstract The G protein–coupled chemokine (C‐C motif) receptor, CCR5, was originally characterized as a protein responding functionally to number of CC chemokines. As with receptors in general, studies indicate that CCR5 plays role inflammatory responses infection, although its exact normal immune function is not completely defined. vast majority research into has been focused on an essential and predominant coreceptor for HIV‐1 entry host cells. Discovery this prompted by the elucidation individuals homozygous 32 bp deletion gene do express receptor at cell surface, consequence, are remarkably resistant apparently possess no other clear phenotype. Multiple followed ultimate aim identifying drugs physically blocked prevent entry, thus provide new approach treating infection AIDS, world's biggest infectious disease killer. To end, functional antagonists potent anti–HIV‐1 activity have discovered, best exemplified maraviroc, first oral drug treatment 10 years. In chapter, specific methods used characterize primary pharmacology apply data generated enable discovery, notably HIV potentially inflammatory‐based indications, described.

参考文章(37)
Manoussos Perros, Patrick Dorr, Graham Rickett, Method for identifying CCR5 receptor antagonists by measuring residency time ,(2003)
Christophe Combadiere, Sunil K. Ahuja, H. Lee Tiffany, Philip M. Murphy, Cloning and functional expression of CC CKR5, a human monocyte CC chemokine receptor selective for MIP-1(alpha), MIP-1(beta), and RANTES. Journal of Leukocyte Biology. ,vol. 60, pp. 147- 152 ,(1996) , 10.1002/JLB.60.1.147
Ben Haworth, Hong Lin, Mark Fidock, Pat Dorr, Philip G. Strange, Allosteric effects of antagonists on signalling by the chemokine receptor CCR5 Biochemical Pharmacology. ,vol. 74, pp. 891- 897 ,(2007) , 10.1016/J.BCP.2007.06.032
B. Sauer, N. Henderson, Site-specific DNA recombination in mammalian cells by the Cre recombinase of bacteriophage P1. Proceedings of the National Academy of Sciences of the United States of America. ,vol. 85, pp. 5166- 5170 ,(1988) , 10.1073/PNAS.85.14.5166
Anja Mueller, Nasir G Mahmoud, Marc C Goedecke, Jane A McKeating, Philip G Strange, Pharmacological characterization of the chemokine receptor, CCR5 British Journal of Pharmacology. ,vol. 135, pp. 1033- 1043 ,(2002) , 10.1038/SJ.BJP.0704540
Jean Labrecque, Virginia Anastassov, Gloria Lau, Marilyn Darkes, Renee Mosi, Simon P. Fricker, The Development of an Europium-GTP Assay to Quantitate Chemokine Antagonist Interactions for CXCR4 and CCR5 Assay and Drug Development Technologies. ,vol. 3, pp. 637- 648 ,(2005) , 10.1089/ADT.2005.3.637
Iva Navratilova, Marianna Dioszegi, David G. Myszka, Analyzing ligand and small molecule binding activity of solubilized GPCRs using biosensor technology. Analytical Biochemistry. ,vol. 355, pp. 132- 139 ,(2006) , 10.1016/J.AB.2006.04.021
Carolyn Napier, Harriet Sale, Michael Mosley, Graham Rickett, Pat Dorr, Roy Mansfield, Mark Holbrook, Molecular cloning and radioligand binding characterization of the chemokine receptor CCR5 from rhesus macaque and human Biochemical Pharmacology. ,vol. 71, pp. 163- 172 ,(2005) , 10.1016/J.BCP.2005.10.024
Patrick Dorr, Mike Westby, Susan Dobbs, Paul Griffin, Becky Irvine, Malcolm Macartney, Julie Mori, Graham Rickett, Caroline Smith-Burchnell, Carolyn Napier, Rob Webster, Duncan Armour, David Price, Blanda Stammen, Anthony Wood, Manos Perros, Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity Antimicrobial Agents and Chemotherapy. ,vol. 49, pp. 4721- 4732 ,(2005) , 10.1128/AAC.49.11.4721-4732.2005